Surgical and Oncologic Outcomes of Nipple-Sparing Mastectomy for a Cohort of Breast Cancer Patients, Including Cases with High-Risk Features.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
08 2020
Historique:
received: 17 12 2019
revised: 20 02 2020
accepted: 01 03 2020
pubmed: 20 4 2020
medline: 9 10 2021
entrez: 20 4 2020
Statut: ppublish

Résumé

Nipple-sparing mastectomy (NSM) remains controversial in patients with high-risk breast cancer. The objective of this study was to assess surgical and oncologic outcomes of NSM and to evaluate associations of outcomes with high-risk features. A retrospective review was conducted of all NSM cases performed for breast cancer at 2 academic cancer centers between January 2013 and August 2018. Of the 175 patients who underwent NSM, 13 (7.4%) had locally advanced breast cancer (LABC), 52 (29.2%) had previous neoadjuvant chemotherapy, 21 (12.0%) had previous radiation therapy, 40 (22.8%) received postmastectomy radiation, 27 (15.4%) had de-epithelialized skin reduction, and 13 (7.4%) had free nipple grafting. The median duration of follow-up was 24 months. Nipple necrosis (4 cases; 2.2%) was associated with previous radiation (9.5%; P = .018), skin reduction (11.1%; P = .001), and nipple grafting (15.4%; P = .001). The nipple-areolar complex margin (NAC) was involved with invasive disease in 1 case. Local recurrence occurred in 8 cases (4.6%), with 1 in-NAC recurrence. Overall survival was 98.3%, and disease-free survival (DFS) was 88.6%. LABC was associated with worse DFS (hazard ratio, 4.28; P = .011), with all 4 recurrences being distant. Previous radiation, skin reduction, and nipple grafting are associated with an increased risk of NAC necrosis. None of these should be considered absolute contraindications, but patients should be counseled appropriately. Although LABC is associated with worse DFS, relapses are systemic. Longer follow-up is needed to establish oncologic safety in unselected breast cancer patients.

Sections du résumé

BACKGROUND
Nipple-sparing mastectomy (NSM) remains controversial in patients with high-risk breast cancer. The objective of this study was to assess surgical and oncologic outcomes of NSM and to evaluate associations of outcomes with high-risk features.
METHODS
A retrospective review was conducted of all NSM cases performed for breast cancer at 2 academic cancer centers between January 2013 and August 2018.
RESULTS
Of the 175 patients who underwent NSM, 13 (7.4%) had locally advanced breast cancer (LABC), 52 (29.2%) had previous neoadjuvant chemotherapy, 21 (12.0%) had previous radiation therapy, 40 (22.8%) received postmastectomy radiation, 27 (15.4%) had de-epithelialized skin reduction, and 13 (7.4%) had free nipple grafting. The median duration of follow-up was 24 months. Nipple necrosis (4 cases; 2.2%) was associated with previous radiation (9.5%; P = .018), skin reduction (11.1%; P = .001), and nipple grafting (15.4%; P = .001). The nipple-areolar complex margin (NAC) was involved with invasive disease in 1 case. Local recurrence occurred in 8 cases (4.6%), with 1 in-NAC recurrence. Overall survival was 98.3%, and disease-free survival (DFS) was 88.6%. LABC was associated with worse DFS (hazard ratio, 4.28; P = .011), with all 4 recurrences being distant.
CONCLUSIONS
Previous radiation, skin reduction, and nipple grafting are associated with an increased risk of NAC necrosis. None of these should be considered absolute contraindications, but patients should be counseled appropriately. Although LABC is associated with worse DFS, relapses are systemic. Longer follow-up is needed to establish oncologic safety in unselected breast cancer patients.

Identifiants

pubmed: 32305298
pii: S1526-8209(20)30048-3
doi: 10.1016/j.clbc.2020.03.001
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-358

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Elena Parvez (E)

McGill University Health Center, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Karyne Martel (K)

Department of Surgery, Saint-Jerome Hospital, Saint-Jerome, QC, Canada.

Dominique Morency (D)

McGill University Health Center, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Sinziana Dumitra (S)

McGill University Health Center, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Sir Mortimer B. David Jewish General Hospital, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Ari N Meguerditchian (AN)

McGill University Health Center, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Tassos Dionisopoulos (T)

Division of Plastic and Reconstructive Surgery, Department of Surgery, McGill University, Montreal, QC, Canada; Sir Mortimer B. David Jewish General Hospital, Montreal, QC, Canada.

Sarkis Meterissian (S)

McGill University Health Center, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Mark Basik (M)

Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Sir Mortimer B. David Jewish General Hospital, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada.

Jean-François Boileau (JF)

Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Sir Mortimer B. David Jewish General Hospital, Montreal, QC, Canada; Division of General Surgery, Department of Surgery, McGill University, Montreal, QC, Canada. Electronic address: jean-francois.boileau@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH